- Home
- SMHI vs UNCY Comparison
SMHI vs UNCY Comparison
Compare SMHI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMHI | UNCY |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.2M | 141.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SMHI | UNCY |
|---|---|---|
| Price | $6.86 | $6.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 109.1K | ★ 488.8K |
| Earning Date | 02-25-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,311,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.63 | $3.71 |
| 52 Week High | $7.88 | $11.00 |
Technical Indicators
Market Signals| Indicator | SMHI | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 62.26 |
| Support Level | $5.86 | $6.01 |
| Resistance Level | $6.40 | $7.19 |
| Average True Range (ATR) | 0.27 | 0.47 |
| MACD | 0.08 | 0.10 |
| Stochastic Oscillator | 95.87 | 85.89 |
Price Performance
Historical ComparisonAbout SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.